ArticleCell chemical biology2019

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Marc Hafner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.